P 20, onwards of the preso I attached a few posts up describes the commercial approach in some detail. The "reimbursement strategies" they've mentioned for some time still sound a bit formative in my view, so I'm also a bit cautious.
- Forums
- Commodities
- Biotech Analysts $4M pa
Biotech Analysts $4M pa, page-22
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)